2257 Stock Overview An RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sirnaomics Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sirnaomics Historical stock prices Current Share Price HK$3.41 52 Week High HK$41.00 52 Week Low HK$2.35 Beta -0.27 1 Month Change 21.79% 3 Month Change 7.91% 1 Year Change -91.32% 3 Year Change n/a 5 Year Change n/a Change since IPO -95.62%
Recent News & Updates
Mincong Huang Resigns as Non-Executive Director of Sirnaomics Ltd Dec 06
Sirnaomics Ltd. Announces Executive Changes Dec 02
Sirnaomics Ltd. Announces Resignation of Shing Mo Han, Yvonne as Independent Non-Executive Director Nov 27
Sirnaomics Ltd. Announces Board and Committee Changes Oct 22
Sirnaomics Ltd. Appoints Poon Hung Fai as Executive Director Oct 17
Sirnaomics Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20 See more updates
Mincong Huang Resigns as Non-Executive Director of Sirnaomics Ltd Dec 06
Sirnaomics Ltd. Announces Executive Changes Dec 02
Sirnaomics Ltd. Announces Resignation of Shing Mo Han, Yvonne as Independent Non-Executive Director Nov 27
Sirnaomics Ltd. Announces Board and Committee Changes Oct 22
Sirnaomics Ltd. Appoints Poon Hung Fai as Executive Director Oct 17
Sirnaomics Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20
Gore Range Capital LLC and Sirnaomics Ltd. Announces Management of the New Venture Sagesse Bio, Inc Aug 06
Sirnaomics Ltd. Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases Jul 12
Sirnaomics Announces Completion Of STP707 Phase I Clinical Study Withstrong Safety Profile and Stable Disease Activityfor the Treatment of Pancreatic Cancer Patients Jun 28
Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer May 18
Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director May 11
Sirnaomics Ltd., Annual General Meeting, Jun 20, 2024 Mar 28
Board Member recently sold HK$14m worth of stock Mar 21
New minor risk - Financial data availability Mar 17
Sirnaomics Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 14
Board Member recently sold HK$8.1m worth of stock Mar 07
Now 29% undervalued after recent price drop Feb 22
New major risk - Revenue and earnings growth Dec 16
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment Dec 06
China Chief Scientific Officer recently bought HK$2.8m worth of stock Dec 04
Sirnaomics Ltd. Announces Executive Changes Dec 01
Sirnaomics Ltd. Presents Positive Clinical Data of STP705 for Focal Fat Reduction Nov 02
Sirnaomics Ltd. Announces Appointment of Chief Strategy Officer and Resignation of Joint Company Secretary Sep 02
Sirnaomics Ltd. Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors Aug 31
Sirnaomics Ltd. to Report Q2, 2023 Results on Aug 30, 2023 Aug 11
Sirnaomics Ltd. Appoints Francois Lebel as Senior Vice President for Preclinical and Clinical Development Jul 29
Sirnaomics Ltd. Establishes Strategic Partnership with Edirna Inc Jul 06
Sirnaomics Advances STP705 for Squamous Cellcarcinoma in Situ into Late-Stage Clinical development Jun 20
Sirnaomics Ltd. Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty Jun 06
Sirnaomics Ltd. Doses the First Participant in Phase I Clinical Study of Galnac-Based Rnai Therapeutic STP122G for Anticoagulant Treatment Jun 02
Sirnaomics Ltd. to Receive Subsidy for Subsidy HKSTP Clinical Translational Catalyst Plan May 18
China Chief Scientific Officer recently sold HK$3.0m worth of stock May 06
Board Member exercised options and sold HK$2.2m worth of stock Apr 22
Sirnaomics Ltd. Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers Feb 02
China Chief Scientific Officer exercised options to buy HK$22m worth of stock. Jan 06
China Chief Scientific Officer recently sold HK$702k worth of stock Dec 23
Sirnaomics Ltd. Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors Dec 21
Sirnaomics Ltd. Announces Positive Interim Datafrom Phase IIB Clinical Trial of Stp705 in Adultswith Cutaneous Squamous Cell Carcinoma in Situ Dec 15 Sirnaomics Ltd. Announces CFO Changes
Less than half of directors are independent Nov 16
Sirnaomics Ltd. Announces Estimated Commercialization Timeline of STP705 Nov 10
Sirnaomics Ltd. Doses First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment Nov 08
China Chief Scientific Officer recently sold HK$1.7m worth of stock Sep 27
Sirnaomics to Present Latest Developments on Sirna Therapeutics for Cancer and Galaheadtm Platform Programs At the 2Nd Annual Oligonucleotide Therapeutics and Delivery Conference Sep 21
China Chief Scientific Officer exercised options to buy HK$14m worth of stock. Sep 05
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma Aug 30
Sirnaomics Ltd. Advances Galahead-Based RNAi Therapeutics for Treatment of Complement-Related Diseases Aug 27
Sirnaomics Ltd. Announces Resignation of Mr. Da Liu as Non-Executive Director with Effect from September 30, 2022 Aug 24
Sirnaomics Ltd. Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer in SITU Aug 19
Sirnaomics Ltd. to Report First Half, 2022 Results on Aug 30, 2022 Aug 18
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics Aug 16
Sirnaomics Ltd. Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment Jul 26
Sirnaomics Ltd. Announces Board Changes Jul 20
Sirnaomics Ltd. Announces Publication of STP705 Clinical Study Results for Treatment of is SCC in the Peer-Reviewed Journal of Drugs in Dermatology Jun 16
Sirnaomics Ltd. Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment May 31
Non Executive Director recently sold HK$2.1m worth of stock May 31
Sirnaomics Ltd. Presents Clinical Study Results and Development Strategy for Cancer RNA Therapeutics At the 2022 Pre-Asco China Summit May 20
Less than half of directors are independent Apr 27
Sirnaomics Ltd. Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis Apr 06
Sirnaomics Ltd., Annual General Meeting, Jun 28, 2022 Apr 01
Sirnaomics Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 23
Sirnaomics Ltd. Announces Interim Data from Phase II Clinical Trial of Stp705 for Treatment of Cutaneous Basal Cell Carcinoma Feb 24
Sirnaomics Ltd. Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC) Feb 17
Sirnaomics Launches Phase I Clinical Trial of Rnai Therapeutic Stp707 Delivered Systemically for the Treatment of Solid Tumors Feb 10
Non Executive Director recently bought HK$371k worth of stock Jan 13
Non Executive Director recently bought HK$11m worth of stock Jan 06
Less than half of directors are independent Dec 30
Sirnaomics Ltd. has completed an IPO in the amount of HKD 496.886 million. Dec 29 Shareholder Returns 2257 HK Biotechs HK Market 7D -3.9% -3.9% -0.5% 1Y -91.3% -5.7% 19.9%
See full shareholder returns
Return vs Market: 2257 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility Is 2257's price volatile compared to industry and market? 2257 volatility 2257 Average Weekly Movement 12.8% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 2257 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2257's weekly volatility (13%) has been stable over the past year.
About the Company Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors.
Show more Sirnaomics Ltd. Fundamentals Summary How do Sirnaomics's earnings and revenue compare to its market cap? 2257 fundamental statistics Market cap HK$296.04m Earnings (TTM ) -HK$636.02m Revenue (TTM ) HK$8.38m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2257 income statement (TTM ) Revenue US$1.08m Cost of Revenue US$0 Gross Profit US$1.08m Other Expenses US$82.88m Earnings -US$81.80m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.94 Gross Margin 100.00% Net Profit Margin -7,587.85% Debt/Equity Ratio -2.4%
How did 2257 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 23:57 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sirnaomics Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null China International Capital Corporation Limited Ziyu He China International Capital Corporation Limited LINDA SHU HSBC
Show 1 more analysts 
